Drug Profile

Research programme: cancer therapeutics - CK Life Sciences

Alternative Names: CKBP 002; CKBP 004

Latest Information Update: 04 Nov 2017

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CK Life Sciences
Developer Cedars-Sinai Health System; CK Life Sciences; University of California at Los Angeles
Class
Mechanism of Action Extracellular signal-regulated MAP kinase inhibitors; Mitogen-activated protein kinase inhibitors; Raf kinase inhibitors; STAT3 transcription factor inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in Hong Kong
04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA
06 Jul 2011 Preclinical development is ongoing in Hong Kong and USA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com